CLAL BIOTECHNOLOGY INDUSTRIES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.8 ILa | +0.99% |
|
-4.90% | +2.77% |
| Sales 2022 | 370K 99.42K 37M | Sales 2023 | 104K 27.95K 10.4M | Capitalization | 62.27M 16.73M 6.23B |
|---|---|---|---|---|---|
| Net income 2022 | -61M -16.39M -6.1B | Net income 2023 | -31M -8.33M -3.1B | EV / Sales 2022 | 331 x |
| Net Debt 2022 | 23.85M 6.41M 2.38B | Net Debt 2023 | 22.4M 6.02M 2.24B | EV / Sales 2023 | 814 x |
| P/E ratio 2022 |
-1.6
x | P/E ratio 2023 |
-2.01
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 34.65% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.99% | ||
| 1 week | -4.90% | ||
| Current month | -7.69% | ||
| 1 month | -21.84% | ||
| 3 months | -10.53% | ||
| 6 months | +3.29% | ||
| Current year | +2.77% |
1 week
39.30
42.90
1 month
39.3052.50
Current year
36.6053.00
1 year
36.6058.40
3 years
36.60267.80
5 years
36.60267.80
10 years
36.60943.00
| Managers | Title | Age | Since |
|---|---|---|---|
Assaf Segal
CEO | Chief Executive Officer | 51 | 15-06-30 |
Liat Nissan
DFI | Director of Finance/CFO | 46 | - |
Arnon Aharon
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 03-05-08 | |
Yuval Yanai
BRD | Director/Board Member | 71 | 15-11-17 |
Gad Keren
BRD | Director/Board Member | 73 | 20-02-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-13 | 40.8 | +0.99% | 65,415 |
| 24-06-10 | 40.4 | -3.12% | 242,907 |
| 24-06-09 | 41.7 | -2.80% | 102,747 |
| 24-06-06 | 42.9 | 0.00% | 151,723 |
| 24-06-05 | 42.9 | -4.45% | 35,916 |
Delayed Quote TEL AVIV STOCK EXCHANGE, June 13, 2024 at 10:24 am EDT
More quotes
Clal Biotechnology Industries Ltd (CBI) is an Israel-based biotechnology investment company. CBI's investments are targeted at bio-pharmaceutical companies, which are at different stages of research and development. The Company is a 59%-owned subsidiary of Clal Industries and Investments Ltd. (CII) that is part of IDB group. Clal Biotechnology Industries Ltd. has a number of portfolio companies, namely Andromeda Biotech Ltd., engaged in the field of type 1 diabetes; D-Pharm Ltd and Trombutech, engaged in the field of ischemic stroke; Mediwound Ltd., engaged in burn and wound management; Biokine Ltd, Biocancell Ltd and CureTech, engaged in the field of cancer; Braintact, engaged in the CNS field and Polyheal Ltd, engaged in wound management, among others.
Sector
Investment Holding Companies
| 1st Jan change | Capi. | |
|---|---|---|
| +2.77% | 17.22M | |
| +22.76% | 83.83B | |
| +13.38% | 18.46B | |
| +57.55% | 17.41B | |
| +9.39% | 14.88B | |
| -4.60% | 12.46B | |
| +0.88% | 11.13B | |
| +8.12% | 10.99B | |
| +24.37% | 9.84B | |
| -5.29% | 9.42B |
- Stock Market
- Equities
- CBI Stock
